Next Article in Journal
Cytokinesis D is Mediated by Cortical Flow of Dividing Cells Instead of Chemotaxis
Previous Article in Journal
Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology
Article Menu

Export Article

Open AccessFeature PaperReview

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

1
Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, Germany
2
German Center for Translational Cancer Research (DKTK), 80337 Munich, Germany
*
Author to whom correspondence should be addressed.
Cells 2019, 8(5), 472; https://doi.org/10.3390/cells8050472 (registering DOI)
Received: 26 April 2019 / Revised: 14 May 2019 / Accepted: 15 May 2019 / Published: 17 May 2019
  |  
PDF [1600 KB, uploaded 17 May 2019]
  |  

Abstract

Cancer therapy has entered a new era, transitioning from unspecific chemotherapeutic agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric antigen receptor (CAR) T cells have shown unparalleled therapeutic potential in treating refractory hematological malignancies. In contrast, solid tumors pose a much greater challenge to CAR T cell therapy, which has yet to be overcome. As this novel therapeutic modality matures, increasing effort is being invested to determine the optimal structure and properties of CARs to facilitate the transition from empirical testing to the rational design of CAR T cells. In this review, we highlight how individual CAR domains contribute to the success and failure of this promising treatment modality and provide an insight into the most notable advances in the field of CAR T cell engineering. View Full-Text
Keywords: CAR T cell; chimeric antigen receptor; immunotherapy; adoptive cell therapy CAR T cell; chimeric antigen receptor; immunotherapy; adoptive cell therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Stoiber, S.; Cadilha, B.L.; Benmebarek, M.-R.; Lesch, S.; Endres, S.; Kobold, S. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. Cells 2019, 8, 472.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top